- Home
- DMAC vs CBAN Comparison
DMAC vs CBAN Comparison
Compare DMAC & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- CBAN
- Stock Information
- Founded
- DMAC 2000
- CBAN 1975
- Country
- DMAC United States
- CBAN United States
- Employees
- DMAC N/A
- CBAN N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- CBAN Major Banks
- Sector
- DMAC Health Care
- CBAN Finance
- Exchange
- DMAC Nasdaq
- CBAN Nasdaq
- Market Cap
- DMAC 310.1M
- CBAN 300.7M
- IPO Year
- DMAC N/A
- CBAN 1998
- Fundamental
- Price
- DMAC $7.06
- CBAN $15.99
- Analyst Decision
- DMAC Strong Buy
- CBAN
- Analyst Count
- DMAC 3
- CBAN 0
- Target Price
- DMAC $12.33
- CBAN N/A
- AVG Volume (30 Days)
- DMAC 262.5K
- CBAN 50.6K
- Earning Date
- DMAC 11-12-2025
- CBAN 10-22-2025
- Dividend Yield
- DMAC N/A
- CBAN 2.88%
- EPS Growth
- DMAC N/A
- CBAN 26.78
- EPS
- DMAC N/A
- CBAN 1.59
- Revenue
- DMAC N/A
- CBAN $122,550,000.00
- Revenue This Year
- DMAC N/A
- CBAN $21.97
- Revenue Next Year
- DMAC N/A
- CBAN $27.53
- P/E Ratio
- DMAC N/A
- CBAN $10.06
- Revenue Growth
- DMAC N/A
- CBAN 12.48
- 52 Week Low
- DMAC $3.19
- CBAN $13.99
- 52 Week High
- DMAC $7.49
- CBAN $18.49
- Technical
- Relative Strength Index (RSI)
- DMAC 57.38
- CBAN 40.96
- Support Level
- DMAC $6.64
- CBAN $15.81
- Resistance Level
- DMAC $7.13
- CBAN $16.90
- Average True Range (ATR)
- DMAC 0.27
- CBAN 0.44
- MACD
- DMAC -0.00
- CBAN -0.04
- Stochastic Oscillator
- DMAC 77.21
- CBAN 13.33
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.